Thomsen P H, Ebbesen C, Persson C
Psychiatric Hospital for Children and Adolescents, University Hospital of Aarhus, Risskov, Denmark.
J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):895-902. doi: 10.1097/00004583-200108000-00010.
The primary purpose of the study was to describe tolerability and effectiveness of citalopram in the treatment of adolescent obsessive-compulsive disorder (OCD).
Thirty nondepressed patients (15 females, 15 males) with a mean age of 13.7 years (range 13-18 years) were treated for their OCD with citalopram in an open-label, flexible-dose study (range of dose 20-70 mg; mean dose 46.5 mg). All patients were referred to Aarhus University Hospital. The patients were monitored for 1 to 2 years. The mean total score on the Yale-Brown Obsessive Compulsive Scale (child or adult version) was 28.7 at base-line, 23.3 after 10 weeks of treatment, 20.0 after 6 months, 18.4 after 1 year, and 17.9 after 2 years (from baseline to 2 years of treatment: t = 11.65; p < .001).
Seventy percent showed a decrease in total Yale-Brown Obsessive Compulsive Scale score in excess of 35% from baseline to 1 year of treatment. Twenty percent still had a score of greater than 20 after 1 year of treatment, indicating that clinically they still had OCD. Side effects were similar to those reported from the use of other selective serotonin reuptake inhibitors (SSRIs). No patient was excluded because of serious side effects during the 1 year of observation.
The clinical effectiveness and tolerability of citalopram in the long-term treatment seem to be comparable with the observations of other SSRIs in childhood and adolescent OCD. A further, statistically significant reduction is provided by an extended treatment period of up to 1 year.
本研究的主要目的是描述西酞普兰治疗青少年强迫症（OCD）的耐受性和有效性。
30名无抑郁症状的患者（15名女性，15名男性），平均年龄13.7岁（范围13 - 18岁），在一项开放标签、灵活剂量的研究中接受西酞普兰治疗OCD（剂量范围20 - 70毫克；平均剂量46.5毫克）。所有患者均转诊至奥胡斯大学医院。对患者进行了1至2年的监测。耶鲁-布朗强迫症量表（儿童或成人版）的平均总分在基线时为28.7，治疗10周后为23.3，6个月后为20.0，1年后为18.4，2年后为17.9（从基线到治疗2年：t = 11.65；p <.001）。
70%的患者从基线到治疗1年，耶鲁-布朗强迫症量表总分下降超过35%。20%的患者在治疗1年后得分仍大于20，表明临床上他们仍患有强迫症。副作用与使用其他选择性5-羟色胺再摄取抑制剂（SSRIs）所报告的相似。在1年的观察期内，没有患者因严重副作用而被排除。
西酞普兰在长期治疗中的临床有效性和耐受性似乎与其他SSRIs在儿童和青少年强迫症中的观察结果相当。延长治疗期至1年可进一步实现具有统计学意义的降低。
